Sodium Borocaptate and Boronopheynlalanine Alone or in Combination as Capture Agents for BNCT of the F98 Rat Glioma

Barth, Rolf F.; Rotaru, Joan H.; Staubus, Alfred E.; Soloway, Albert H.; Moeschberger, Melvin L.

doi:10.1007/978-1-4757-9567-7_109

Cited by 5 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently in animal studies, BPA and BSH have been used in combination. 137,138 These agents have been administered, following blood-brain barrier disruption, via the internal carotid artery that provides the blood supply to the tumor. The results have shown measurable increases in tumor boron concentration and following neutron irradiation, 25% of the rats bearing the highly refractory F98 glioma implanted intracranially have been cured.…”

Section: "Second Generation" Boron Compoundsmentioning

confidence: 99%

The Chemistry of Neutron Capture Therapy

et al. 1998

Self Cite

View full text Add to dashboard Cite

Section: "Second Generation" Boron Compoundsmentioning

confidence: 99%

The Chemistry of Neutron Capture Therapy

et al. 1998

Self Cite

View full text Add to dashboard Cite

Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation

2003

View full text Add to dashboard Cite

Development of any therapeutic modality can be facilitated by the use of the appropriate animal models to assess its efficacy. This report primarily will focus on our studies using the F98 and 9L rat glioma models to evaluate the effectiveness of boron neutron capture therapy (BNCT) of brain tumors. Following intracerebral implantation the biological behavior of each tumor resembles that of human high grade gliomas in a number of ways. In both models, glioma cells were implanted intracerebrally into syngeneic Fischer rats and approximately 10-14 days later BNCT was initiated at the Brookhaven National Laboratory Medical Research Reactor. Two low molecular weight (M(r) < 210Da) 10B-containing drugs, boronophenylalanine (BPA) and/or sodium borocaptate (BSH) were used as capture agents, either alone or in combination with each other. The 9L gliosarcoma, which has been difficult to cure by means of either chemo- or radiotherapy alone, was readily curable by BNCT. The best survival data were obtained using BPA at a dose of 1200 mg/kg (64.8mg 10B), administered intraperitoneally (i.p.), with a 100% survival rate at 8 months. In contrast, the F98 glioma has been refractory to all therapeutic modalities. Tumor bearing animals, which had received 500 mg/kg (27 mg 10B) of BPA, or an equivalent amount of BSH i.v., had mean survival time (MST) of 37 and 33 days, respectively, compared to 29 days for irradiated controls. The best survival data with the F98 glioma model were obtained using BPA + BSH in combination, administered intra-arterially via the internal carotid artery (i.c.) with hyperosmotic mannitol induced blood-brain barrier disruption (BBB-D). The MST was 140 days with a cure rate of 25%, compared to a MST of 73 days with a 5% cure rate without BBB-D, and 41 days following i.v. administration of both drugs. A modest but significant increase in MST also was observed in rats that received intracarotid (i.c.) BPA in combination with Cereport (RMP-7), which produced a pharmacologically mediated opening of the BBB. Studies also have been carried out with the F98 glioma to determine whether an X-ray boost could enhance the efficacy of BNCT, and it was shown that there was a significant therapeutic gain. Finally, molecular targeting of the epidermal growth factor receptor (EGFR) has been investigated using F98 glioma cells, which had been transfected with the gene encoding EGFR and, intratumoral injection of boronated EGF as the delivery agent, followed by BNCT. These studies demonstrated that there was specific targeting of EGFR and provided proof of principle for the use of high molecular weight, receptor targeting-boron delivery agents. Finally, a xenograft model for melanoma metastatic to the brain has been developed using a human melanoma (MRA27), stereotactically implanted into the brains of nude rats, and these studies demonstrated that BNCT either cured or significantly prolonged the survival of tumor-bearing rats. It remains to be determined, which, if any, of these experimental approaches will be translated int...

show abstract

Pharmacokinetic study of BSH and BPA in simultaneous use for BNCT

et al. 2006

View full text Add to dashboard Cite

In order to improve the effectiveness of boron neutron capture therapy (BNCT) for malignant gliomas, we examined the optimization of the administration of boron compounds in brain tumor animal model. We analyzed the concentration of boron atoms in intracranial C6 glioma -bearing rats using inductively coupled plasma atomic emission spectrometry. Each tumor-bearing rat received one of two different amounts of sodium borocaptate (BSH) and/or 500 mg/kg of boronophenylalanine (BPA) via intraperitoneal injection. We compared the boron concentrations of the tumor, the contralateral normal brain and the blood in rats of 3 different treatment groups (BSH alone, BPA alone and a combination of both BSH and BPA). Our results show that the tumor boron concentration increased much more than 30 microg/g by the coadministration of both compounds. Additionally, the blood boron concentration remained below 30 microg/g and the boron concentration in the normal brain was low (mean 4.7+/-1.1 microg/g). Even in comparison with the administration of BPA alone, coadministration of BPA and BSH shows an improved tumor/normal brain ratio of boron concentrations.

show abstract

Sodium Borocaptate and Boronopheynlalanine Alone or in Combination as Capture Agents for BNCT of the F98 Rat Glioma

Cited by 5 publications

References 6 publications

The Chemistry of Neutron Capture Therapy

The Chemistry of Neutron Capture Therapy

Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation

Pharmacokinetic study of BSH and BPA in simultaneous use for BNCT

Contact Info

Product

Resources

About